Benzoyl Peroxide/Tretinoin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Benzoyl Peroxide/Tretinoin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Benzoyl Peroxide/Tretinoin can convert its Small molecule drug profile and RARα x RARβ2 x RARγ biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Benzoyl Peroxide/Tretinoin (query alias: Benzoyl Peroxide/Tretinoin) |
|---|---|
| Modality / target | Small molecule drug; RARα x RARβ2 x RARγ; RARα agonists, RARβ2 agonists, RARγ agonists |
| Highest global status | Approved |
| Originator | Sol-Gel Technologies Ltd. |
| Active developers | Sol-Gel Technologies Ltd., Searchlight Pharma, Inc., Mayne Pharma Ltd. |
The MCP disease footprint includes Acne Vulgaris. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20261443 | Phase 3 | 进行中 （尚未招募） | 450 | Not disclosed |
| CTRI/2025/12/098417 | Phase 2/3 | Not Yet Recruiting | 64 | Not disclosed |
| JPRN-UMIN000060219 | Not Applicable | 参加者募集終了‐試験継続中/No longer recruiting | 200 | 手術終了時に採取した皮膚検体における Cutibacterium acnes の培養陽性率 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Adherence to topical acne treatment improves as regimen complexity decreases
Not Applicable; n=55; evaluation: Positive. Reported fields: Adherence(≥60% of days) = 42.0 % ; Adherence(≥60% of days) = 82.0 % ; Adherence(≥60% of days) = 32.0 %
Acne and Skin Oiliness Improvements With Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% (CAB) Gel: Post Hoc Analysis of 12-Week and 24-Week Studies
Phase 2/3; n=1165; evaluation: Positive. Reported fields: Treatment Success(12 week) = 18.3 % ; Treatment Success(12 week) = 50.8 %
Pseudofolliculitis barbae diagnosis and management in U.S. Veterans, Fiscal Years 2016-2022
Not Applicable; n=23760; evaluation: Negative. Reported fields: Age at first PFB diagnosis = 48.4 year ( 14.0)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Benzoyl Peroxide/Tretinoin addresses Acne Vulgaris. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-04-17 | Sol-Gel and Galderma entered an mutual termination for the the exclusive five-year license agreement for EPSOLAY and TWYNEO | Approved | US$24.0M stated total |
| 2025-04-17 | Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. | Approved | US$16.0M stated total |
| 2024-07-25 | Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
